nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—CYP2C9—Capecitabine—esophageal cancer	0.0791	0.665	CbGbCtD
Nilutamide—CYP2C9—Cisplatin—esophageal cancer	0.0398	0.335	CbGbCtD
Nilutamide—Flutamide—CYP1B1—esophageal cancer	0.0268	0.792	CrCbGaD
Nilutamide—Enzalutamide—ABCB1—esophageal cancer	0.00702	0.208	CrCbGaD
Nilutamide—Interstitial pneumonia—Methotrexate—esophageal cancer	0.00613	0.0225	CcSEcCtD
Nilutamide—Pain—Carboplatin—esophageal cancer	0.00561	0.0206	CcSEcCtD
Nilutamide—Body temperature increased—Carboplatin—esophageal cancer	0.00519	0.019	CcSEcCtD
Nilutamide—Nocturia—Capecitabine—esophageal cancer	0.00429	0.0157	CcSEcCtD
Nilutamide—Lung disorder—Methotrexate—esophageal cancer	0.00418	0.0153	CcSEcCtD
Nilutamide—Interstitial lung disease—Methotrexate—esophageal cancer	0.00418	0.0153	CcSEcCtD
Nilutamide—Cataract—Capecitabine—esophageal cancer	0.00418	0.0153	CcSEcCtD
Nilutamide—Bone pain—Capecitabine—esophageal cancer	0.00415	0.0152	CcSEcCtD
Nilutamide—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00398	0.0146	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00392	0.0144	CcSEcCtD
Nilutamide—Melaena—Capecitabine—esophageal cancer	0.00388	0.0143	CcSEcCtD
Nilutamide—Blood creatinine increased—Cisplatin—esophageal cancer	0.00367	0.0135	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00353	0.0129	CcSEcCtD
Nilutamide—Abnormal vision—Capecitabine—esophageal cancer	0.00347	0.0127	CcSEcCtD
Nilutamide—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00332	0.0122	CcSEcCtD
Nilutamide—Libido decreased—Capecitabine—esophageal cancer	0.00311	0.0114	CcSEcCtD
Nilutamide—Hot flush—Capecitabine—esophageal cancer	0.00309	0.0113	CcSEcCtD
Nilutamide—Menopausal symptoms—Capecitabine—esophageal cancer	0.00306	0.0112	CcSEcCtD
Nilutamide—Arthritis—Capecitabine—esophageal cancer	0.00297	0.0109	CcSEcCtD
Nilutamide—Cardiac failure—Capecitabine—esophageal cancer	0.00296	0.0109	CcSEcCtD
Nilutamide—Melaena—Methotrexate—esophageal cancer	0.00289	0.0106	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00289	0.0106	CcSEcCtD
Nilutamide—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00286	0.0105	CcSEcCtD
Nilutamide—Blood creatinine increased—Capecitabine—esophageal cancer	0.0027	0.00992	CcSEcCtD
Nilutamide—Urinary tract disorder—Cisplatin—esophageal cancer	0.00268	0.00982	CcSEcCtD
Nilutamide—Urethral disorder—Cisplatin—esophageal cancer	0.00266	0.00974	CcSEcCtD
Nilutamide—Gynaecomastia—Methotrexate—esophageal cancer	0.00265	0.00972	CcSEcCtD
Nilutamide—Dry skin—Capecitabine—esophageal cancer	0.00265	0.00971	CcSEcCtD
Nilutamide—Visual impairment—Cisplatin—esophageal cancer	0.00261	0.00958	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.0026	0.00954	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00255	0.00934	CcSEcCtD
Nilutamide—Influenza—Capecitabine—esophageal cancer	0.00249	0.00915	CcSEcCtD
Nilutamide—Angina pectoris—Capecitabine—esophageal cancer	0.00243	0.00892	CcSEcCtD
Nilutamide—Alopecia—Cisplatin—esophageal cancer	0.00239	0.00878	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00232	0.00851	CcSEcCtD
Nilutamide—Visual disturbance—Methotrexate—esophageal cancer	0.00227	0.00832	CcSEcCtD
Nilutamide—Weight decreased—Capecitabine—esophageal cancer	0.00226	0.00828	CcSEcCtD
Nilutamide—Hyperglycaemia—Capecitabine—esophageal cancer	0.00225	0.00826	CcSEcCtD
Nilutamide—Pneumonia—Capecitabine—esophageal cancer	0.00224	0.00821	CcSEcCtD
Nilutamide—Depression—Capecitabine—esophageal cancer	0.00222	0.00814	CcSEcCtD
Nilutamide—Ill-defined disorder—Cisplatin—esophageal cancer	0.00219	0.00803	CcSEcCtD
Nilutamide—Anaemia—Cisplatin—esophageal cancer	0.00218	0.008	CcSEcCtD
Nilutamide—Urinary tract infection—Capecitabine—esophageal cancer	0.00216	0.00793	CcSEcCtD
Nilutamide—Malaise—Cisplatin—esophageal cancer	0.00213	0.0078	CcSEcCtD
Nilutamide—Haematuria—Capecitabine—esophageal cancer	0.00212	0.00778	CcSEcCtD
Nilutamide—Leukopenia—Cisplatin—esophageal cancer	0.00211	0.00775	CcSEcCtD
Nilutamide—Rhinitis—Capecitabine—esophageal cancer	0.002	0.00735	CcSEcCtD
Nilutamide—Hypoaesthesia—Capecitabine—esophageal cancer	0.00199	0.00729	CcSEcCtD
Nilutamide—Discomfort—Cisplatin—esophageal cancer	0.00198	0.00728	CcSEcCtD
Nilutamide—Urinary tract disorder—Capecitabine—esophageal cancer	0.00197	0.00724	CcSEcCtD
Nilutamide—Oedema peripheral—Capecitabine—esophageal cancer	0.00197	0.00722	CcSEcCtD
Nilutamide—Urethral disorder—Capecitabine—esophageal cancer	0.00196	0.00718	CcSEcCtD
Nilutamide—Oedema—Cisplatin—esophageal cancer	0.00192	0.00706	CcSEcCtD
Nilutamide—Visual impairment—Capecitabine—esophageal cancer	0.00192	0.00706	CcSEcCtD
Nilutamide—Hyperhidrosis—Cisplatin—esophageal cancer	0.00186	0.00683	CcSEcCtD
Nilutamide—Anorexia—Cisplatin—esophageal cancer	0.00183	0.00673	CcSEcCtD
Nilutamide—Alopecia—Capecitabine—esophageal cancer	0.00176	0.00648	CcSEcCtD
Nilutamide—Paraesthesia—Cisplatin—esophageal cancer	0.00173	0.00634	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00173	0.00633	CcSEcCtD
Nilutamide—Dyspnoea—Cisplatin—esophageal cancer	0.00172	0.0063	CcSEcCtD
Nilutamide—Erectile dysfunction—Methotrexate—esophageal cancer	0.00171	0.00628	CcSEcCtD
Nilutamide—Back pain—Capecitabine—esophageal cancer	0.00168	0.00617	CcSEcCtD
Nilutamide—Decreased appetite—Cisplatin—esophageal cancer	0.00167	0.00614	CcSEcCtD
Nilutamide—Pneumonia—Methotrexate—esophageal cancer	0.00167	0.00611	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00166	0.0061	CcSEcCtD
Nilutamide—Depression—Methotrexate—esophageal cancer	0.00165	0.00606	CcSEcCtD
Nilutamide—Pain—Cisplatin—esophageal cancer	0.00165	0.00604	CcSEcCtD
Nilutamide—Ill-defined disorder—Capecitabine—esophageal cancer	0.00161	0.00592	CcSEcCtD
Nilutamide—Anaemia—Capecitabine—esophageal cancer	0.00161	0.0059	CcSEcCtD
Nilutamide—Sweating—Methotrexate—esophageal cancer	0.00159	0.00583	CcSEcCtD
Nilutamide—Feeling abnormal—Cisplatin—esophageal cancer	0.00159	0.00582	CcSEcCtD
Nilutamide—Haematuria—Methotrexate—esophageal cancer	0.00158	0.00579	CcSEcCtD
Nilutamide—Malaise—Capecitabine—esophageal cancer	0.00157	0.00575	CcSEcCtD
Nilutamide—Syncope—Capecitabine—esophageal cancer	0.00156	0.00572	CcSEcCtD
Nilutamide—Leukopenia—Capecitabine—esophageal cancer	0.00156	0.00571	CcSEcCtD
Nilutamide—Loss of consciousness—Capecitabine—esophageal cancer	0.00153	0.00561	CcSEcCtD
Nilutamide—Body temperature increased—Cisplatin—esophageal cancer	0.00152	0.00558	CcSEcCtD
Nilutamide—Cough—Capecitabine—esophageal cancer	0.00152	0.00557	CcSEcCtD
Nilutamide—Hypertension—Capecitabine—esophageal cancer	0.0015	0.00551	CcSEcCtD
Nilutamide—Chest pain—Capecitabine—esophageal cancer	0.00148	0.00543	CcSEcCtD
Nilutamide—Urinary tract disorder—Methotrexate—esophageal cancer	0.00147	0.00539	CcSEcCtD
Nilutamide—Discomfort—Capecitabine—esophageal cancer	0.00146	0.00537	CcSEcCtD
Nilutamide—Urethral disorder—Methotrexate—esophageal cancer	0.00146	0.00535	CcSEcCtD
Nilutamide—Dry mouth—Capecitabine—esophageal cancer	0.00145	0.00531	CcSEcCtD
Nilutamide—Visual impairment—Methotrexate—esophageal cancer	0.00143	0.00526	CcSEcCtD
Nilutamide—AR—Coregulation of Androgen receptor activity—CCND1—esophageal cancer	0.00142	0.00247	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CREBBP—esophageal cancer	0.00142	0.00247	CbGpPWpGaD
Nilutamide—Oedema—Capecitabine—esophageal cancer	0.00142	0.00521	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—RB1—esophageal cancer	0.00141	0.00246	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00141	0.00245	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.00141	0.00245	CbGpPWpGaD
Nilutamide—Shock—Capecitabine—esophageal cancer	0.0014	0.00512	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—SMAD4—esophageal cancer	0.00139	0.00242	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00139	0.00242	CbGpPWpGaD
Nilutamide—Asthenia—Cisplatin—esophageal cancer	0.00138	0.00507	CcSEcCtD
Nilutamide—Hyperhidrosis—Capecitabine—esophageal cancer	0.00137	0.00503	CcSEcCtD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00137	0.00238	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—ADH7—esophageal cancer	0.00136	0.00236	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00135	0.00236	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—esophageal cancer	0.00135	0.00236	CbGpPWpGaD
Nilutamide—Anorexia—Capecitabine—esophageal cancer	0.00135	0.00496	CcSEcCtD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00135	0.00234	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00134	0.00233	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—ADH1B—esophageal cancer	0.00133	0.00232	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00133	0.00231	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BAX—esophageal cancer	0.00132	0.00229	CbGpPWpGaD
Nilutamide—Diarrhoea—Cisplatin—esophageal cancer	0.00132	0.00483	CcSEcCtD
Nilutamide—Alopecia—Methotrexate—esophageal cancer	0.00131	0.00482	CcSEcCtD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00128	0.00223	CbGpPWpGaD
Nilutamide—Insomnia—Capecitabine—esophageal cancer	0.00128	0.00471	CcSEcCtD
Nilutamide—Paraesthesia—Capecitabine—esophageal cancer	0.00127	0.00467	CcSEcCtD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00127	0.0022	CbGpPWpGaD
Nilutamide—Dyspnoea—Capecitabine—esophageal cancer	0.00126	0.00464	CcSEcCtD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00126	0.00219	CbGpPWpGaD
Nilutamide—Back pain—Methotrexate—esophageal cancer	0.00125	0.00459	CcSEcCtD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00125	0.00217	CbGpPWpGaD
Nilutamide—Dyspepsia—Capecitabine—esophageal cancer	0.00125	0.00458	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—CYP26A1—esophageal cancer	0.00124	0.00216	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.00124	0.00216	CbGpPWpGaD
Nilutamide—Decreased appetite—Capecitabine—esophageal cancer	0.00123	0.00453	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00122	0.00449	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00122	0.00213	CbGpPWpGaD
Nilutamide—Vomiting—Cisplatin—esophageal cancer	0.00122	0.00449	CcSEcCtD
Nilutamide—Rash—Cisplatin—esophageal cancer	0.00121	0.00445	CcSEcCtD
Nilutamide—Pain—Capecitabine—esophageal cancer	0.00121	0.00445	CcSEcCtD
Nilutamide—Constipation—Capecitabine—esophageal cancer	0.00121	0.00445	CcSEcCtD
Nilutamide—Dermatitis—Cisplatin—esophageal cancer	0.00121	0.00445	CcSEcCtD
Nilutamide—AR—Generic Transcription Pathway—NR1I2—esophageal cancer	0.00121	0.00211	CbGpPWpGaD
Nilutamide—Ill-defined disorder—Methotrexate—esophageal cancer	0.0012	0.00441	CcSEcCtD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.0012	0.00208	CbGpPWpGaD
Nilutamide—Anaemia—Methotrexate—esophageal cancer	0.0012	0.00439	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—ADH1B—esophageal cancer	0.00119	0.00207	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.00119	0.00207	CbGpPWpGaD
Nilutamide—Feeling abnormal—Capecitabine—esophageal cancer	0.00117	0.00429	CcSEcCtD
Nilutamide—Malaise—Methotrexate—esophageal cancer	0.00117	0.00428	CcSEcCtD
Nilutamide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00116	0.00426	CcSEcCtD
Nilutamide—Leukopenia—Methotrexate—esophageal cancer	0.00116	0.00425	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.00115	0.00201	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.00115	0.00201	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GSTO1—esophageal cancer	0.00115	0.00201	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—esophageal cancer	0.00114	0.00199	CbGpPWpGaD
Nilutamide—Nausea—Cisplatin—esophageal cancer	0.00114	0.0042	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTO1—esophageal cancer	0.00114	0.00198	CbGpPWpGaD
Nilutamide—Cough—Methotrexate—esophageal cancer	0.00113	0.00414	CcSEcCtD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00113	0.00196	CbGpPWpGaD
Nilutamide—Abdominal pain—Capecitabine—esophageal cancer	0.00112	0.00412	CcSEcCtD
Nilutamide—Body temperature increased—Capecitabine—esophageal cancer	0.00112	0.00412	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.00111	0.00193	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP26A1—esophageal cancer	0.00111	0.00193	CbGpPWpGaD
Nilutamide—Chest pain—Methotrexate—esophageal cancer	0.0011	0.00404	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—esophageal cancer	0.0011	0.00191	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00109	0.0019	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00109	0.0019	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.00109	0.0019	CbGpPWpGaD
Nilutamide—Discomfort—Methotrexate—esophageal cancer	0.00109	0.00399	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.00109	0.00189	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—esophageal cancer	0.00105	0.00183	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CCND1—esophageal cancer	0.00105	0.00183	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—EP300—esophageal cancer	0.00104	0.00181	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTO1—esophageal cancer	0.00103	0.00179	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00103	0.00179	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Methotrexate—esophageal cancer	0.00102	0.00375	CcSEcCtD
Nilutamide—Asthenia—Capecitabine—esophageal cancer	0.00102	0.00374	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—CDKN1A—esophageal cancer	0.00102	0.00177	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTO1—esophageal cancer	0.00102	0.00177	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.00101	0.00176	CbGpPWpGaD
Nilutamide—Anorexia—Methotrexate—esophageal cancer	0.00101	0.00369	CcSEcCtD
Nilutamide—Pruritus—Capecitabine—esophageal cancer	0.001	0.00368	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000996	0.00173	CbGpPWpGaD
Nilutamide—Diarrhoea—Capecitabine—esophageal cancer	0.000971	0.00356	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—EP300—esophageal cancer	0.000967	0.00168	CbGpPWpGaD
Nilutamide—Insomnia—Methotrexate—esophageal cancer	0.000955	0.00351	CcSEcCtD
Nilutamide—Paraesthesia—Methotrexate—esophageal cancer	0.000948	0.00348	CcSEcCtD
Nilutamide—Dyspnoea—Methotrexate—esophageal cancer	0.000942	0.00346	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—ALDH2—esophageal cancer	0.00094	0.00164	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000939	0.00163	CbGpPWpGaD
Nilutamide—Dizziness—Capecitabine—esophageal cancer	0.000938	0.00344	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—CASP8—esophageal cancer	0.000935	0.00163	CbGpPWpGaD
Nilutamide—Dyspepsia—Methotrexate—esophageal cancer	0.00093	0.00341	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—RB1—esophageal cancer	0.000927	0.00161	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000926	0.00161	CbGpPWpGaD
Nilutamide—Decreased appetite—Methotrexate—esophageal cancer	0.000918	0.00337	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—esophageal cancer	0.000918	0.0016	CbGpPWpGaD
Nilutamide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000912	0.00335	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.000909	0.00158	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000906	0.00158	CbGpPWpGaD
Nilutamide—Pain—Methotrexate—esophageal cancer	0.000903	0.00331	CcSEcCtD
Nilutamide—Vomiting—Capecitabine—esophageal cancer	0.000902	0.00331	CcSEcCtD
Nilutamide—Rash—Capecitabine—esophageal cancer	0.000895	0.00328	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—GSTT1—esophageal cancer	0.000894	0.00156	CbGpPWpGaD
Nilutamide—Dermatitis—Capecitabine—esophageal cancer	0.000894	0.00328	CcSEcCtD
Nilutamide—Headache—Capecitabine—esophageal cancer	0.000889	0.00326	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—CYP2A6—esophageal cancer	0.000884	0.00154	CbGpPWpGaD
Nilutamide—Feeling abnormal—Methotrexate—esophageal cancer	0.00087	0.00319	CcSEcCtD
Nilutamide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000864	0.00317	CcSEcCtD
Nilutamide—CYP2C8—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000863	0.0015	CbGpPWpGaD
Nilutamide—Nausea—Capecitabine—esophageal cancer	0.000843	0.00309	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—ALDH2—esophageal cancer	0.000839	0.00146	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—PTGS1—esophageal cancer	0.000838	0.00146	CbGpPWpGaD
Nilutamide—Abdominal pain—Methotrexate—esophageal cancer	0.000835	0.00306	CcSEcCtD
Nilutamide—Body temperature increased—Methotrexate—esophageal cancer	0.000835	0.00306	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—EGFR—esophageal cancer	0.000824	0.00143	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BCL2—esophageal cancer	0.000802	0.0014	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTT1—esophageal cancer	0.000798	0.00139	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP2A6—esophageal cancer	0.000789	0.00137	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000774	0.00135	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000771	0.00134	CbGpPWpGaD
Nilutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.00077	0.00134	CbGpPWpGaD
Nilutamide—AR—Gene Expression—SMG6—esophageal cancer	0.00077	0.00134	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000765	0.00133	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.000761	0.00132	CbGpPWpGaD
Nilutamide—Asthenia—Methotrexate—esophageal cancer	0.000758	0.00278	CcSEcCtD
Nilutamide—CYP2C19—Biological oxidations—PTGS1—esophageal cancer	0.000748	0.0013	CbGpPWpGaD
Nilutamide—Pruritus—Methotrexate—esophageal cancer	0.000747	0.00274	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000728	0.00127	CbGpPWpGaD
Nilutamide—Diarrhoea—Methotrexate—esophageal cancer	0.000723	0.00265	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.00072	0.00125	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP1B1—esophageal cancer	0.000713	0.00124	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000703	0.00122	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000702	0.00122	CbGpPWpGaD
Nilutamide—Dizziness—Methotrexate—esophageal cancer	0.000698	0.00256	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—CCND1—esophageal cancer	0.000688	0.0012	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000687	0.0012	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.000682	0.00119	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000682	0.00119	CbGpPWpGaD
Nilutamide—Vomiting—Methotrexate—esophageal cancer	0.000672	0.00246	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—CYP19A1—esophageal cancer	0.00067	0.00117	CbGpPWpGaD
Nilutamide—Rash—Methotrexate—esophageal cancer	0.000666	0.00244	CcSEcCtD
Nilutamide—Dermatitis—Methotrexate—esophageal cancer	0.000665	0.00244	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.000665	0.00116	CbGpPWpGaD
Nilutamide—Headache—Methotrexate—esophageal cancer	0.000662	0.00243	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000661	0.00115	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.000646	0.00112	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP1B1—esophageal cancer	0.000636	0.00111	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EP300—esophageal cancer	0.000634	0.0011	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.000631	0.0011	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000627	0.00109	CbGpPWpGaD
Nilutamide—Nausea—Methotrexate—esophageal cancer	0.000627	0.0023	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000617	0.00107	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000614	0.00107	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP19A1—esophageal cancer	0.000598	0.00104	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00059	0.00103	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NR1I2—esophageal cancer	0.000583	0.00101	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.00058	0.00101	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—SMAD4—esophageal cancer	0.000573	0.000997	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000572	0.000995	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.00057	0.000993	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000559	0.000973	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MYC—esophageal cancer	0.000552	0.000961	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.000552	0.00096	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000545	0.000949	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EGFR—esophageal cancer	0.00054	0.00094	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000538	0.000936	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.000525	0.000914	CbGpPWpGaD
Nilutamide—AR—Gene Expression—HIST1H2BM—esophageal cancer	0.0005	0.000871	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000464	0.000808	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000458	0.000796	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—esophageal cancer	0.000453	0.000789	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000448	0.000779	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000422	0.000735	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000414	0.000721	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000405	0.000705	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000388	0.000676	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PSME2—esophageal cancer	0.000388	0.000676	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PSME1—esophageal cancer	0.000388	0.000676	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000383	0.000666	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000378	0.000658	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000376	0.000654	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NOTCH3—esophageal cancer	0.000366	0.000637	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000362	0.000629	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SLC52A3—esophageal cancer	0.00036	0.000626	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—BLVRB—esophageal cancer	0.00036	0.000626	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.00033	0.000574	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NOTCH2—esophageal cancer	0.000329	0.000572	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000322	0.00056	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—BLVRB—esophageal cancer	0.000321	0.000559	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SLC52A3—esophageal cancer	0.000321	0.000559	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CA1—esophageal cancer	0.000306	0.000533	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SLC10A2—esophageal cancer	0.000306	0.000533	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000293	0.00051	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000293	0.00051	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000287	0.0005	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CA2—esophageal cancer	0.00028	0.000487	CbGpPWpGaD
Nilutamide—AR—Gene Expression—SMAD4—esophageal cancer	0.000276	0.00048	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000274	0.000476	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CA1—esophageal cancer	0.000273	0.000475	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SLC10A2—esophageal cancer	0.000273	0.000475	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000262	0.000456	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ADH7—esophageal cancer	0.00026	0.000453	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PLCE1—esophageal cancer	0.00026	0.000453	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000257	0.000448	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CA2—esophageal cancer	0.00025	0.000435	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CA1—esophageal cancer	0.000249	0.000434	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000249	0.000434	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000244	0.000425	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PLCE1—esophageal cancer	0.000232	0.000404	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ADH7—esophageal cancer	0.000232	0.000404	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.00023	0.0004	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ADH1B—esophageal cancer	0.000228	0.000397	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CA2—esophageal cancer	0.000228	0.000397	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—MYC—esophageal cancer	0.000227	0.000395	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000223	0.000388	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TYMP—esophageal cancer	0.000218	0.00038	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP26A1—esophageal cancer	0.000212	0.000369	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000212	0.000369	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000212	0.000369	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000209	0.000364	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ALOX15—esophageal cancer	0.000207	0.00036	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ADH1B—esophageal cancer	0.000204	0.000354	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NOTCH1—esophageal cancer	0.000203	0.000354	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TPI1—esophageal cancer	0.000197	0.000343	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTO1—esophageal cancer	0.000197	0.000343	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TYMP—esophageal cancer	0.000195	0.000339	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP26A1—esophageal cancer	0.000189	0.00033	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ALDOB—esophageal cancer	0.000189	0.000329	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000186	0.000323	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ALOX15—esophageal cancer	0.000185	0.000321	CbGpPWpGaD
Nilutamide—AR—Gene Expression—CREBBP—esophageal cancer	0.000184	0.000321	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GAPDH—esophageal cancer	0.000182	0.000317	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CRABP1—esophageal cancer	0.00018	0.000314	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000178	0.000309	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TPI1—esophageal cancer	0.000176	0.000306	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTO1—esophageal cancer	0.000176	0.000306	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP26A1—esophageal cancer	0.000173	0.0003	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GNG7—esophageal cancer	0.000172	0.000299	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ALDOB—esophageal cancer	0.000169	0.000294	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ALOX15—esophageal cancer	0.000168	0.000293	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GAPDH—esophageal cancer	0.000162	0.000283	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CRABP1—esophageal cancer	0.000161	0.00028	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ALDH2—esophageal cancer	0.000161	0.00028	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTO1—esophageal cancer	0.000161	0.000279	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TPI1—esophageal cancer	0.000161	0.000279	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ALDOB—esophageal cancer	0.000154	0.000268	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GNG7—esophageal cancer	0.000153	0.000267	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTT1—esophageal cancer	0.000153	0.000266	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP2A6—esophageal cancer	0.000151	0.000263	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000151	0.000262	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GAPDH—esophageal cancer	0.000148	0.000258	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CRABP1—esophageal cancer	0.000147	0.000256	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ALDH2—esophageal cancer	0.000144	0.00025	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ENO1—esophageal cancer	0.000143	0.000249	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTGS1—esophageal cancer	0.000143	0.000249	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PSME1—esophageal cancer	0.000141	0.000246	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PSME2—esophageal cancer	0.000141	0.000246	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GNG7—esophageal cancer	0.00014	0.000243	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTT1—esophageal cancer	0.000137	0.000238	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP2A6—esophageal cancer	0.000135	0.000235	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000134	0.000234	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ALDH2—esophageal cancer	0.000131	0.000228	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTGS1—esophageal cancer	0.000128	0.000223	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ENO1—esophageal cancer	0.000128	0.000223	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PSME2—esophageal cancer	0.000126	0.000219	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PSME1—esophageal cancer	0.000126	0.000219	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTT1—esophageal cancer	0.000124	0.000217	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000123	0.000215	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP2A6—esophageal cancer	0.000123	0.000214	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000123	0.000213	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP1B1—esophageal cancer	0.000122	0.000212	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTGS1—esophageal cancer	0.000117	0.000203	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ENO1—esophageal cancer	0.000117	0.000203	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PSME1—esophageal cancer	0.000115	0.0002	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PSME2—esophageal cancer	0.000115	0.0002	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP19A1—esophageal cancer	0.000115	0.000199	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.00011	0.000192	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MYC—esophageal cancer	0.000109	0.00019	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP1B1—esophageal cancer	0.000109	0.000189	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—HMOX1—esophageal cancer	0.000105	0.000182	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000103	0.000178	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP19A1—esophageal cancer	0.000102	0.000178	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.0001	0.000175	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ABCB1—esophageal cancer	0.0001	0.000175	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP1B1—esophageal cancer	9.92e-05	0.000173	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—HMOX1—esophageal cancer	9.33e-05	0.000162	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP19A1—esophageal cancer	9.33e-05	0.000162	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.16e-05	0.000159	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ABCB1—esophageal cancer	8.96e-05	0.000156	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—HMOX1—esophageal cancer	8.51e-05	0.000148	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.35e-05	0.000145	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ABCB1—esophageal cancer	8.17e-05	0.000142	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.59e-05	0.000132	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.77e-05	0.000118	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CREBBP—esophageal cancer	6.71e-05	0.000117	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.18e-05	0.000107	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NOS3—esophageal cancer	6.01e-05	0.000104	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CREBBP—esophageal cancer	5.99e-05	0.000104	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTGS2—esophageal cancer	5.49e-05	9.56e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CREBBP—esophageal cancer	5.46e-05	9.5e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NOS3—esophageal cancer	5.36e-05	9.33e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTGS2—esophageal cancer	4.9e-05	8.53e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NOS3—esophageal cancer	4.89e-05	8.5e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—EP300—esophageal cancer	4.57e-05	7.95e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTGS2—esophageal cancer	4.47e-05	7.78e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—EP300—esophageal cancer	4.08e-05	7.09e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—EP300—esophageal cancer	3.72e-05	6.47e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CA—esophageal cancer	3.38e-05	5.88e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CA—esophageal cancer	3.02e-05	5.25e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.75e-05	4.79e-05	CbGpPWpGaD
